Tiziana Life Sciences to Showcase Innovations at Annual Conference
TIZIANA LIFE SCIENCES, Ltd. (Nasdaq: TLSA), a pioneering biotechnology company dedicated to developing transformational immunomodulation therapies, recently announced its participation in an upcoming conference aimed at connecting with investors and industry leaders. This year, CEO Ivor Elrifi will engage in a fireside chat, presenting the company's advancements and engaging in one-on-one meetings with potential investors.
Event Participation Details
The 37th Annual Roth Conference will convene an array of sizable companies across various growth sectors. Specific meet-and-greet sessions and panel discussions will be held from March 16 to 18. Tiziana Life Sciences has lined up a virtual presentation on March 18 where Elrifi will elaborate on the company’s promising initiatives, including intranasal foralumab, which has generated significant interest due to its unique approach in addressing critical health issues.
Intranasal Foralumab: A Groundbreaking Therapy
Foralumab, the company’s lead candidate, is a fully human anti-CD3 monoclonal antibody administered intranasally. This innovative therapy has demonstrated the ability to stimulate T regulatory cells, providing a promising avenue for treating conditions like Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS). With current studies showing positive outcomes in those who have undergone the treatment, Tiziana aims to expand its clinical reach, having received FDA approval for more patients to join the Expanded Access Program.
Clinical Development and Patient Outcomes
In an open-label setting, 10 patients with na-SPMS participated in the Expanded Access Program, and all showed either improvement or stability in their conditions within six months. The positive feedback underscores the potential of foralumab in addressing neuroinflammatory disorders. Additionally, a Phase 2a randomized trial is underway, evaluating its efficacy further, suggesting that the future of this therapy could reshape treatment paradigms in neurology.
Understanding Tiziana Life Sciences’ Approach
Tiziana Life Sciences is not just focused on the development of one therapy. The company is revolutionizing the immunotherapy landscape through alternative drug delivery systems that promise enhanced safety and improved efficacy compared to traditional intravenous methods. Their work is reflected in the growing body of research supporting the use of nasal drug administration for various medical conditions, particularly those that affect the immune system.
Innovative Technologies and Future Directions
With several patents pending on their unique delivery techniques, Tiziana is well-positioned to expand its pipeline. Their commitment to innovation is evident as they continue to explore new therapies for neuroinflammatory and neurodegenerative diseases, establishing the company as a frontrunner in the field of immunotherapy.
About the Company
Founded with the mission to advance healthcare through cutting-edge technology, Tiziana Life Sciences stands out in the clinical-stage biopharmaceutical industry. Their dedication to research and development is evident, and they invite those interested in their work to reach out for more information. Tiziana’s projects have the potential to improve treatment methodologies significantly and to offer hope to patients who need it most.
Contact Information
For more details about Tiziana Life Sciences and its innovative therapy pipeline, individuals can visit their official website.
For further inquiries, please contact:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@tizianalifesciences.com
Frequently Asked Questions
What is the focus of Tiziana Life Sciences?
Tiziana Life Sciences is focused on developing groundbreaking immunomodulation therapies, particularly through its lead candidate, intranasal foralumab.
When will Tiziana present at the Roth Conference?
The presentation is scheduled for March 18, 2025, during the 37th Annual Roth Conference.
What is intranasal foralumab?
Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to stimulate T regulatory cells, used primarily for treating multiple sclerosis.
How has foralumab performed in clinical trials?
The therapy has shown promising results, with all 10 participants in an open-label study demonstrating improvement or stability in their conditions.
How can I contact Tiziana Life Sciences for more information?
Interested individuals can reach out to Tiziana Life Sciences via email or phone for inquiries regarding their therapies.
